A Trial of Grazax in Subjects With Hayfever

A Phase III Trial Assessing the Efficacy and Safety of Grazax in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis With or Without Asthma

The trial is performed to evaluate the efficacy and safety of specific immunotherapy with Grazax for treatment of grass pollen induced allergy.

Inclusion Criteria:

• History of grass pollen allergy
• Positive skin prick test to grass
• Positive specific IgE to grass

Exclusion Criteria

• FEV1 <70% of predicted value